felt Thanks
As we reflect on 2024, we are filled with gratitude for the incredible generosity of our supporters. Your contributions have been instrumental in advancing the mission of the DCM Foundation and the Genetic Cardiomyopathy Awareness Consortium (GCAC). Together, we’ve achieved impactful milestones, bringing hope and tangible benefits to patients and families affected by dilated cardiomyopathy (DCM)
Read More… from Thank You for Your Support: 2024 Impact Highlights
Press release excerpt: “Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024 Highlights Recently Presented Insights on Pediatric MYBPC3-associated HCM Disease Burden SOUTH SAN FRANCISCO, Calif.,
Are you affected by cardiomyopathy? Please CLICK HERE to access a 5-10 minute survey. Learn more below. CureHeart is developing genetic therapies to treat inherited cardiomyopathy. https://cureheart.org/patients The CureHeart project brings together researchers across the UK, US and Asia, and commercial as well as patient advocacy partners, to develop effective genetic therapies for cardiomyopathies. The
Read More… from Cardiomyopathy Study Participants Needed for 5 Minute Survey
Clinical Trial Now Enrolling for Patients with Dilated Cardiomyopathy (DCM) due to Genetic Mutations or Unknown Causes Bristol Myers Squibb is conducting a clinical trial in patients with DCM due to genetic mutations or unknown causes. Details of the study and eligibility requirements are listed below and participating in such research can help advance therapies
Please click on this link or the image above to view a recording of this webinar and learn about: Myths and Truths About Clinical Trials Industry experts discuss the Myths and Truths of Clinical Trials on a panel discussion Learn about the phases and average timeline for clinical trials Hear about the measures taken to ensure
Learn about the important role of GENETICS in cardiomyopathy and celebrate the LAUNCH of the Genetic Cardiomyopathy Awareness Consortium (“GCAC”). Getting more people genetically tested can save lives and advance therapies! In this webinar, hear from other cardiomyopathy patients and learn about: The role genetics plays in cardiomyopathy How easy and affordable it is to
Read More… from Cardiomyopathy & Genetics Webinar / Launch of “GCAC” – Get the Facts & Save Lives
New targets for gene therapy may have been identified by researchers at Harvard Medical School and Brigham and Women’s Hospital. They studied the specific cell changes that lead to heart failure diseases like dilated cardiomyopathy. “Our findings hold enormous potential for rethinking how we treat heart failure and point to the importance of understanding its
Read More… from New Potential Targets for Gene Therapy in Heart Failure Patients
A Scientific Network Session focused on Lamin A/C Cardiomyopathy was held on April 13, 2022. The goal of this session was for LMNA experts to share information regarding current strategies, crazy ideas, and future collaborations to discover a cure for the LMNA genetic mutation. A recording of this session is now available – please click here
Tenaya Therapeutics, a biotechnology company committed to discovering, developing, and delivering curative therapies that address the underlying causes of heart disease, is sponsoring a study to better understand pediatric cardiomyopathy due to the MYBPC3 mutation. The MyClimb Natural History Study is designed to collect and evaluate information on the course of cardiomyopathy in children and adolescents <18
Read More… from Natural History Study Seeks Participants with MYBPC3 Genetic Mutation
Our peers at Cardiomyopathy UK are working alongside CureHeart to develop the first cures for inherited cardiomyopathies, like DCM. You can support this extraordinary effort. Please watch this YouTube video to learn more: https://bit.ly/3Bxm1MU
Read More… from Researching Cures for Inherited Cardiomyopathies
